MediWound delivered a robust performance in Q3 2025, advancing clinical trials for EscharEx and expanding NexoBrid manufacturing, while bolstering its financial foundation with strategic financing.
- Enrollment in the VALUE Phase III trial for EscharEx is progressing well, with 40 sites activated in the U.S. and Europe, although adjustments may affect timelines.
- NexoBrid's manufacturing capacity has expanded sixfold, positioning the company for future growth amidst rising global demand.
- Recent equity financing of $30 million enhances MediWound's financial flexibility to pursue growth strategies.
- NexoBrid achieved record quarterly revenues, with a 38% year-over-year increase reported by partner Vericel, indicating strong market penetration.
- Updates from Medicare on reimbursement rates may create competitive advantages for EscharEx in the complex wound care market.
Community Discussion